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ABSTRACT
Introduction: Many biological markers are used as prognostic and predictive indicators in invasive breast 
cancers management. Among them, tumour size, grade, patho-morphological subtype, hormone receptors 
status and HER2 receptor expression in addition to Ki-67 proliferative index. Also, they play a key role in 
adjuvant treatment decision making. Our aim was to evaluate the association between Ki-67 proliferative 
index and breast cancer immunological subtype.
Material and methods: A total of 515 early invasive patients were enrolled, tumour biological characteristics 
as histopathological subtype, immune-histo-chemistry (ER,PR,HER2) status and Ki-67 proliferation index 
values have been collected. The Ki-67 index level of 20%, was used as the cut-off point to differentiate 
between low and high Ki-67 expression levels. Statistical analysis has been performed using the Chi 
square test online tool.
Results: In this cohort, about 42%, 33%, 7%, and 18% of the cases were grouped as luminal A-like, luminal 
B-like, HER2 enriched subtype, and triple-negative, respectively. All luminal A-like patients had Ki-67 level 
less than 20%. About 3% of the cohort, are luminal B-like tumours with Ki-67 level less than 20%, where 
30.3% of the patients were luminal B-like tumours with Ki-67 level ≥ 20%. In HER2 enriched subtype, Ki-
67 of < 20% level seen in 1.9% of cases, and Ki-67 levels ≥ 20% was observed in 5.2% of the cases. In 
the triple-negative group, Ki-67 was 20% or higher in 16% of cases, and only 1.7% of patients had Ki-67 
level less than 20%. 
Conclusion: Luminal A-like tumours were the most frequently encountered subtype, they have low Ki-67 
levels and are known to be of a low histological grade tumour, and usually associated with a good prog-
nosis. Also, data indicates that high Ki-67 levels are seen more often in Luminal B-Like breast cancers as 
well as in triple-negative breast cancers and HER2 enriched tumours.
Key words: breast neoplasms, Ki-67 proliferation index, eestrogen receptor, Progesterone receptor, HER2
Med Res J 2021; 6 (2): 108–113
Medical Research Journal 2021;
Volume 6, Number 2, 108–113
DOI: 10.5603/MRJ.2021.0026 




According to 2018 WHO reports, breast malignancy 
is the most common cancer among the female gender 
with the lifetime risk of 12%. It is followed by colorectal, 
lung, cervical and thyroid cancer as the most common 
cancers in women [1, 2]. The previous reports showed 
that breast cancer immuno-histochemical subtypes 
have a real impact on the disease prognosis and to 
the response to hormonal blockade treatment and 
chemotherapy. In 1983, Gerdes et al., described the 
Ki-67 protein, which is a nonhistone protein, works as 
a surfactant and helps the chromosomes to preserve 
discrete confirmations in a condensed state. If the Ki-
67 coating layer is missing, during the metaphase of 
the cell cycle, the chromosomes remodelled into an un-
shaped or amorphous mass, where the cell division and 
replication will be compromised [3]. Ki-67 proliferation 
index significance has been widely studied, it is used 
as a diagnostic, prognostic and predictive marker in the 
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management of cancers originated in breast, pancreas, 
colon and prostate in addition to endometriosis [4–8]. 
Tumours that express a higher levels of Ki-67 prolifer-
ation index have a worse prognosis than tumors that 
express lower levels [9]. 
Material and methods
A total of 515 patients were included in this study. 
All the patients had an early/loco-regional breast cancer 
diagnosis in the period between 2014–2020. Informed 
consent from the patients was not necessary, however, 
the study results were a secondary outcome of a re-
gional audit which was approved by the Institutional 
Review Board under the number GSART336. After 
the diagnosis, they underwent the recommended 
management. Patients with metastatic disease at pre-
sentation or not fit for curative management has been 
excluded. The medical records have been retrieved, 
the data related to the patients’ demographics, tumour 
biological characteristics as histopathological subtype, 
immune-histo-chemistry (ER, PR, HER2) status and 
Ki-67 proliferation index values have been collected 
and analysed. The Ki-67 index level of 20%, was used 
as the cut-off point to differentiate between low and 
high Ki-67 expression. The statistical analysis has 
been performed using Chi-square test on excel, the 
calculated p-values of less than 0.05 were considered 
statistically significant.
Results
Our retrospective study was carried out on 
515 patients with operable early invasive breast carci-
nomas. The age span of the cohort, ranges between 
27–97 years, with a mean of 63 years. The different 
clinico-histo-pathological parameters of breast cancer 
varieties are shown in (Tab. 1). Among the 515 cases, 
297 patients aged less than 70 years (57.6%) and 
218 (42.3%) aged more than 70 years. In terms of the 
histopathological features, 436 cases (84.6%) were IDC, 
NST (invasive ductal carcinoma, of no special type), 
48 tumours showed invasive lobular carcinoma (ILC) 
(9.3%), 12 (2.3%) cases were papillary carcinoma and 
9 (1.7%) patients had mucinous carcinoma. About 49% 
(254) of the cases were grade II, 32% (166) grade III 
and about 18.4% (95) were grade I tumours (Tab. 1). 
With regard to the female sex hormone expression, the 
ER (Oestrogen receptor) positive expression tumours 
were 72.6% and PR (progesterone receptors) positive 
expression detected in 58% of the cases. Approximately 
17% of tumours were HER2+ (score 3+ or amplified 
FISH test), where 18% of cases were triple-negative 
phenotype. We have used 20% as the cutting point for 
Ki-67 proliferation expression. Ki-67 nuclear positivity 
of ≥ 20 % was detected in 52% (262) of the cases 
(Tab. 1). We have classified the 515 cases according 
to the available immune-phenotyping results into four 
groups: 1) luminal-A like (ER-positive or PR-positive and 
HER2-negative), 2) luminal-B like (ER-positive and/or 
Table 1. Tumour characteristics and its relation to different immuno-histochemical subtypes, % (n)
Criteria All Luminal A-Like Luminal B-like HER2 Enriched Triple-negative P value 
Age (years)
    < 70 57.6% (297) 23% (117) 18% (93) 4.85% (25) 12% (62)
0*    ≥ 70 42.3% (218) 19.2% (99) 15.1% (78) 2.3% (12) 5.6% (29)
Tumour grade
    G I 18.4% (95) 15% (78) 02.9% (15) 0 0.38% (2)
< 0.00001    G II 49% (254) 25% (128) 18% (95) 02.3% (12) 03.7% (19)
    G III 32% (166) 2% (10) 12% (61) 4.85% (25) 13.4% (70)
Ki-67
    < 20% 48% (249) 42% (216) 2.9% (15) 1.9% (10) 1.7% (9)
0.0003    ≥ 20% 52% (266) – 30% (156) 5.2% (27) 16% (82)
Histological subtype
    IDC, NST 84.6% (436) 33% (172) 29% (151) 06.6% (34) 15% (79)
< 0.0001    ILC 09.3% (48) 06.6% (34) 2% (10) 0 0.77% (4)
    Papillary 02.3% (12) 0.77% (4) 1.1% (6) 0.2% (1) 0.2% (1)
    Mucinous 1.7% (9) 1.1% (6) 0.6% (3) 0 0
    Others 2% (10) 0 0 0.2% (1) 1.7% (9)
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Table 2. Ki-67 proliferation index and breast cancer 
phenotypes
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     ER+VE, PR+VE, HER2+VE
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Figure 1. Ki-67 proliferation index value in different subtypes of breast cancers based on immuno-histo-chemistry 
classification
PR-negative and HER2-positive or HER2 negative with 
high Ki-67 levels ), 3) HER2 enriched (ER-negative, 
PR-negative and HER2-positive), and (4) triple-negative 
(ER-negative, PR-negative, HER2-negative), the cases 
distribution in the cohort was 42%, 33%, 8%, and 17.6% 
of the cases, respectively (Tab. 2).
As showed in (Fig.1), luminal B-Like breast cancers 
showed the highest proportion of high Ki6-7 index 
value, 30.3 % (156) of the cohort, followed by tri-
ple-negative breast cancer, 15.9% (82), and the least 
was Her2 enriched subtype, 05.2% (27). Nonetheless, 
luminal A-Like cancers showed the highest proportion 
of low Ki6-7 index value, 42% (216), followed by lu-
minal B-Like cancers with 02.9% (15), triple-negative 
breast cancers were 01.7% (n = 9) and HER2 enriched 
tumours were 1.9% (n = 10). Our data discloses 
a statistically significant correlation between tumour 
grade and Ki-67 proliferative index levels among the 
different histopathological tumour subtypes (P values 
of 0 < 0.00001).
Discussion
Breast cancer is regarded as a heterogeneous dis-
order, tumour detailed assessment and categorization 
into certain immuno-histochemical subtype based on 
molecular studies is recommended to predict disease 
prognosis and facilitate management decisions and 
planning. In addition to the Ki-67 proliferation index, 
many other biomarkers and online tools have been 
utilised to assess the prognosis and disease recur-
rence prediction. These biological criteria include ER 
(Oestrogen Receptor) expression, PR (Progesterone 
Receptor) expression, HER2 (Human Epidermal Growth 
Factor Receptor — type 2) expression, and Oncotype 
DX recurrence score, where the online tools include; 
NPI (Nottingham Prognostic Index) and PREDICT (Tab. 
3). This is required to identify cases associated with 
a sufficiently high risk of disease relapse to warrant 
them adjuvant chemotherapy and prolonged hormon-
al manipulation treatment if appropriate. Assessment 
of the Ki-67 proliferation index is based on IHC (im-
mune-histochemical) staining of the tumour cells for the 
Ki67 protein, it is detected in the active course of the cell 
cycle ( Late G1, S, G2, and M), and not detected during 
Abdalla Saad Abdalla Al-Zawi et al., Ki-67 and receptor status in breast cancer: a review of 515 cases
111www.journals.viamedica.pl/medical_research_journal
Table 3. Conventional and genomic prognostic factors 
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cancer subtypes Prognostic marker Targeted therapy
Low Ki-67Luminal B 
like Luminal A 
like High Ki-67
Figure 2. Current and potential future utilization of Ki-67 proliferation index in cancer management
G0 and early G1 [1, 10, 11]. The Ki-67 proliferative 
index has value in cancer diagnosis as a cell prolifer-
ation indicator, the cancer tissues show a significantly 
higher expression of Ki-67 proliferative index than in 
healthy tissues [6]. Nagao et al., in 2011, presented 
a cohort of 119 patients treated for prostate cancer, 
the paper concluded that the Ki-67 proliferation index 
is an independent factor for survival rate, this included 
tumour grade and stage [12]. Nielsen et al., in 2013, 
published a result of a prospective 190 patient cohort 
with primary cutaneous melanoma. Also, this study 
concluded that Ki-67 proliferation index was a strong 
prognostic marker in primary cutaneous melanoma [7]. 
Some recent studies revealed that the administration 
of antibodies targeted against the Ki-67 protein was 
shown to result in a slower rate of cell division. This fact 
makes Ki-67 a promising factor for targeted molecular 
cancer therapy. ASOs (Antisense oligonucleotide ) are 
small-sized single-stranded nucleic acids that are used 
as Ki-67 peptide nucleic acid antagonists affects the 
cancer cells proliferation and apoptosis [13]. Another 
field where the Ki-67 proliferation index could be useful 
is monitoring the tumour response to upfront chemo-
therapy prior to surgery, Mukai et al, in 2014, in research 
related to 237 HER2 positive breast cancer patients. The 
response to upfront chemotherapy was assessed using 
pre-chemotherapy, mid-chemotherapy (3 cycles of pa-
clitaxel and trastuzumab) and postoperative Ki-67 pro-
liferation index. The cohort divided into the control arm 
or the Ki-67 response-guided arm (Ki-67 arm). 
The control arm continued the same treatment re-
gardless of the achieved result of the Ki-67 proliferation 
index, where Ki-67 arm group further treatment was 
modified according to the interim Ki-67 index. They 
have found that there was a linear correlation between 
the Ki-67 proliferation index reduction rate at interim 
evaluation and the pathological complete response to 
upfront chemotherapy [14]. In addition to its diagnostic 
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Table 4. Breast cancer molecular subtypes and their criteria [15, 17–19, 25]
Breast cancer subtype Sex hormone, HER2 and cytokeratins 
expression
Incidence Ki-67 Grade Prognosis
Luminal A ER+VE and/or PR+VE, HER2-VE, CK5/6–VE, 
Keratin 8/18+VE
71% Low Low Good
Luminal B ER+VE and/or PR+VE, HER2+VE, CK5/6–VE, 
Keratin 8/18
8%
Luminal B-like ER+VE, any PR, HER2-VE with high K-i67 High
Triple-negative “Basal-like” ER-VE, PR -VE, HER2-VE, CK5/6+VE 15% High Poor
HER2-enriched ER–VE, PR–VE, HER2+, CK5/6–VE 6% High Poor
Normal breast-like group Not classified
and prognostic value, Ki-i7 proliferation index is used to 
differentiate between Luminal A-like and Luminal B-like 
subtypes in ER+VE/HER2–VE breast cancer (Fig.2). 
The main histological breast cancer subtypes have 
been identified according to ER (oestrogen receptor), 
P R ( progesterone receptor), and HER2 (Human Epi-
dermal Growth Factor Receptor — type 2) expression 
(Tab. 4). Additional molecular classification is based 
on gene expression profile studies also is increasingly 
used to categorize different molecular subtypes of 
breast cancer. The subtype luminal type A which is 
the most frequent identified breast cancer subtype is 
strong ER+VE and/or PR+VE/HER2-VE status. These 
tumours are known to be of a low histological grade 
tumour, and usually associated with a good prognosis, 
it forms about 71% of breast cancers, likely to benefit 
from hormonal blockade treatment and may benefit 
from chemotherapy [15, 16] in our cohort, luminal 
A-like tumours are encountered in 42% of cases. The 
luminal B subtype is weak/moderate ER+VE and/or 
PR+VE with HER2+VE (overexpression or amplifica-
tion), this subtype has higher Ki-67 levels than luminal 
A tumours, and it is  encountered in about 8% of 
breast  cancers.  These tumours are likely to benefit 
from neo/adjuvant chemotherapy and may benefit 
from hormonal manipulation therapy in addition to the 
HER2 targeted treatment [17]. Luminal B-like tumours 
are ER+VE and/or PR-VE with HER2-VE expression, 
however, has a high Ki-67 index value. The basal-like 
breast cancer (BLBC), given this name as they are char-
acterized by high expression of genes characteristic of 
normal breast tissue basal epithelial cells as CK 5/6, 
CK14, CK15 and CK17. Most of them (but not all) are 
triple-negative breast cancer (i.e. has a receptor expres-
sion ER-VE, PR–VE, HER2–VE), encountered frequently 
in young premenopausal patients with high BMI. They 
are high-grade tumours, forms about 15% of all invasive 
ductal carcinoma of no special type, associated with 
an aggressive clinical course, often relapsing rapidly 
either loco-regional or as a distant metastatic disease 
and linked to a high mortality rate [18–20].The HER2-E 
(HER2 enriched) subtype tumors have HER2+VE/ER-
VE/PR-VE expression, these tumours are less common 
however some of them are characterized by high-grade 
histology and poor prognosis [21]. A recent systematic 
review and meta-analysis published by Schettini et al. 
from Naples, Italy in 2020, the paper stating that HER2-E 
tumours are associated with a higher likelihood of 
achieving a complete pathological response following 
neoadjuvant anti-HER2-based therapy [22]. Some  pre-
vious reports has stated that, the triple-negative breast 
cancer is associated with the highest Ki-67 index values, 
where the HER2 positive tumours were in second place. 
Looking at the histological subtypes, the observations 
revealed that the metaplastic and medullary breast 
cancers showed a significantly higher Ki-67 proliferative 
index as compared to invasive ductal carcinoma, NST 
[23, 24]. Our cohort showing that luminal B-like cancers 
has the highest Ki-67 index values (30%), followed by 
triple negative breast cancer (16%). Perez-Lopez et 
al., in 2016, presented a series of 680 patients, using 
the Saint Gallen criteria, the cohort was divided in IHC 
subtypes. The prognosis of the groups was analysed. 
It was found the luminal B N0 had the most unfavorable 
prognosis, the other criteria which were associated with 
this group are those of the luminal B tumours as PR 
negative, HER2 positive as well as high Ki-67 prolifer-
ation index expression [24]. Our results show that in 
addition to the luminal B-like cancers, other subtypes 
of breast cancer also has high Ki-67 index values, these 
subtypes include triple-negative breast cancer (16%) 
and HER2 enriched tumours (5.2%). These tumours are 
less common than luminal A tumours, however, some 
of them are characterized by high-grade histology and 
poor prognosis. These findings are in accordance with 
the published researches data.
Conclusion
Generally, this data showed that the majority of the 
cases of low Ki-67 index expression belongs to the 
luminal A-like group, where the majority of cases with 
a high Ki-67 index expression are of non-luminal A-like 
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subtype as luminal B-Like and triple-negative tumours 
(P < 0.00001). The Ki-67 level is regarded as a helpful 
biomarker in breast cancer management, its expression 
is strongly associated with disease aggressiveness and 
prognosis, also it has an additional value, currently is 
considered as a promising therapeutic target in breast 
cancer.      
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